151 related articles for article (PubMed ID: 24034420)
1. Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis.
Uitte de Willige S; Malfliet JJ; Janssen HL; Leebeek FW; Rijken DC
J Thromb Haemost; 2013 Nov; 11(11):2029-36. PubMed ID: 24034420
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.
Lee KN; Jackson KW; Christiansen VJ; Dolence EK; McKee PA
J Thromb Haemost; 2011 May; 9(5):987-96. PubMed ID: 21251197
[TBL] [Abstract][Full Text] [Related]
3. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA
Blood; 2004 May; 103(10):3783-8. PubMed ID: 14751930
[TBL] [Abstract][Full Text] [Related]
4. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.
Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
Blood; 2006 Feb; 107(4):1397-404. PubMed ID: 16223769
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of soluble fibroblast activation protein in arterial thrombosis: determinants and cleavage of its substrate alpha-2-antiplasmin.
Uitte de Willige S; Malfliet JJ; Deckers JW; Dippel DW; Leebeek FW; Rijken DC
Int J Cardiol; 2015 Jan; 178():105-10. PubMed ID: 25464232
[TBL] [Abstract][Full Text] [Related]
6. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.
Lee KN; Jackson KW; Terzyan S; Christiansen VJ; McKee PA
Biochemistry; 2009 Jun; 48(23):5149-58. PubMed ID: 19402713
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.
Abdul S; Peeters M; Brouwers E; Malfliet JJMC; Leebeek FWG; Declerck PJ; Rijken DC; Uitte de Willige S
PLoS One; 2018; 13(5):e0196911. PubMed ID: 29723259
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction.
Uitte de Willige S; Miedzak M; Carter AM; Lisman T; Rosendaal FR; Grant PJ; Philippou H; Ariëns RA
Blood; 2011 Jun; 117(24):6694-701. PubMed ID: 21505192
[TBL] [Abstract][Full Text] [Related]
9. Why alpha-antiplasmin must be converted to a derivative form for optimal function.
Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
J Thromb Haemost; 2007 Oct; 5(10):2095-104. PubMed ID: 17883704
[TBL] [Abstract][Full Text] [Related]
10. The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot.
Uitte de Willige S; Malfliet JJCM; Abdul S; Leebeek FWG; Rijken DC
Thromb Res; 2018 Jun; 166():19-21. PubMed ID: 29649768
[TBL] [Abstract][Full Text] [Related]
11. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.
Christiansen VJ; Jackson KW; Lee KN; McKee PA
Arch Biochem Biophys; 2007 Jan; 457(2):177-86. PubMed ID: 17174263
[TBL] [Abstract][Full Text] [Related]
12. On the localization of the cleavage site in human alpha-2-antiplasmin, involved in the generation of the non-plasminogen binding form.
Abdul S; Dekkers DHW; Ariëns RAS; Leebeek FWG; Rijken DC; Uitte de Willige S
J Thromb Haemost; 2020 May; 18(5):1162-1170. PubMed ID: 32034861
[TBL] [Abstract][Full Text] [Related]
13. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences.
Abdul S; Leebeek FW; Rijken DC; Uitte de Willige S
Blood; 2016 Feb; 127(5):538-45. PubMed ID: 26626994
[TBL] [Abstract][Full Text] [Related]
14. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
15. The alpha-2-antiplasmin Arg407Lys polymorphism is associated with abdominal aortic aneurysm.
Bridge KI; Macrae F; Bailey MA; Johnson A; Philippou H; Scott DJ; Ariens RA
Thromb Res; 2014 Sep; 134(3):723-8. PubMed ID: 25065555
[TBL] [Abstract][Full Text] [Related]
16. Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal.
Lee KN; Jackson KW; Christiansen VJ; Chung KH; McKee PA
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):303-10. PubMed ID: 15320781
[TBL] [Abstract][Full Text] [Related]
17. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.
Christiansen VJ; Jackson KW; Lee KN; McKee PA
Blood; 2007 Jun; 109(12):5286-92. PubMed ID: 17317851
[TBL] [Abstract][Full Text] [Related]
18. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Lee SC; Jackson KW; Tae WC; Schwartzott DG; McKee PA
Thromb Haemost; 1998 Oct; 80(4):637-44. PubMed ID: 9798984
[TBL] [Abstract][Full Text] [Related]
19. Circulating concentrations of fibroblast activation protein α in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
Tillmanns J; Widera C; Habbaba Y; Galuppo P; Kempf T; Wollert KC; Bauersachs J
Int J Cardiol; 2013 Oct; 168(4):3926-31. PubMed ID: 23932048
[TBL] [Abstract][Full Text] [Related]
20. Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
BMC Biotechnol; 2009 Mar; 9():15. PubMed ID: 19257897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]